Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

被引:0
|
作者
Ban, Iulian O. [1 ]
Chabert, Alice [1 ]
Guignard, Thomas [2 ,3 ]
Puechberty, Jacques [2 ,3 ]
Cabello-Aguilar, Simon [1 ,4 ]
Pujol, Pascal [2 ]
Vendrell, Julie A. [1 ]
Solassol, Jerome [1 ,5 ]
机构
[1] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Dept Pathol & Oncobiol, Lab Biol Tumeurs Solides, Montpellier, France
[2] Arnaud de Villeneuve Hosp, Dept Med Genet, Montpellier, France
[3] Univ Montpellier, Ctr Hosp Univ CHU Montpellier, Lab Genet Chromos, Plateforme ChromoStem, Montpellier, France
[4] Ctr Hosp Univ CHU Montpellier, Montpellier BioInformat Clin Diag MOBID, Mol Med & Genom Platform PMMG, Montpellier, France
[5] Univ Montpellier, Inst Rech Cancerol Montpellier IRCM, Inst Canc Montpellier ICM, Montpellier, France
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
PALB2; LGR; breast cancer; long-read sequencing; molecular alteration; MECHANISMS;
D O I
10.3389/fonc.2024.1355715
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance. Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication. Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination. Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells
    Lee, Ji Sun
    Oh, Yunmoon
    Lee, Jin-Sol
    Park, Jae-Hyeon
    Shin, Joo-Kyung
    Han, Joo-Hee
    Kim, Hyung Sik
    Yoon, Sungpil
    IN VIVO, 2022, 36 (05): : 2105 - 2115
  • [32] Enhancing immunotherapy for triple-negative and HER2+breast cancer using EpCAM aptamer-siRNA mediated gene knockdown
    Zhang, Ying
    Lieberman, Judy
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [33] Genetic disruption of CAPNS1 impedes triple-negative breast cancer metastasis: A case for selective calpain-1/2 inhibitors
    Harper, Danielle
    Shapovalov, Ivan
    Cockburn, Samantha
    Min, Jenny
    Gao, Yan
    Greer, Peter A.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12)
  • [34] Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome
    Guerbuez, Ali Fuat
    Eryilmaz, Melek Karakurt
    Yildiz, Oguzhan
    Kilinc, Fahriye
    Araz, Murat
    Artac, Mehmet
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (11) : 986 - 990
  • [35] Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study
    Mejri, Nesrine
    El Benna, Houda
    Rachdi, Haifa
    Labidi, Soumaya
    Benna, Mahdi
    Daoud, Nouha
    Hamdi, Yosr
    Abdelhak, Sonia
    Boussen, Hamouda
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (05) : 204 - 210
  • [36] Long-term survival of a patient with relapsing triple-negative breast cancer stage IIB under surgical treatment and Viscum album extracts - A case report
    Werthmann, Paul Georg
    Kuck, Angela
    Kienle, Gunver S.
    PHYTOMEDICINE, 2019, 61
  • [37] A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
    Shigematsu, Hideo
    Kadoya, Takayuki
    Kobayashi, Yoshie
    Kajitani, Keiko
    Sasada, Tatsunari
    Emi, Akiko
    Masumoto, Norio
    Haruta, Rumi
    Kataoka, Tsuyoshi
    Oda, Miyo
    Arihiro, Kouji
    Okada, Morihito
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2011, 9
  • [38] A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
    Hideo Shigematsu
    Takayuki Kadoya
    Yoshie Kobayashi
    Keiko Kajitani
    Tatsunari Sasada
    Akiko Emi
    Norio Masumoto
    Rumi Haruta
    Tsuyoshi Kataoka
    Miyo Oda
    Kouji Arihiro
    Morihito Okada
    World Journal of Surgical Oncology, 9
  • [39] Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer
    Kim, Soo-Yeon
    Lee, Jinsu
    Cho, Nariya
    Kim, Young-Gon
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [40] Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report
    Azzi, Georges
    Krinshpun, Shifra
    Tin, Antony
    Maninder, Minu
    Malashevich, Allyson Koyen
    Malhotra, Meenakshi
    Vega, Ruben Ruiz
    Billings, Paul R.
    Rodriguez, Angel
    Aleshin, Alexey
    CASE REPORTS IN ONCOLOGY, 2022, 15 (02): : 473 - 479